Kronox Lab Sciences（KRONOX）株式概要クロノックス・ラボ・サイエンシズ社は、ファインケミカル、無機化学品、リン酸塩、金属化学品をインド国内外で製造・販売している。 詳細KRONOX ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績3/6財務の健全性6/6配当金3/6報酬株価収益率（ 19.2 x） Indian市場（ 23.1 x）を下回っています。過去5年間の収益は年間17.7%増加しました。 リスク分析意味のある時価総額がありません ( ₹5B )すべてのリスクチェックを見るKRONOX Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₹Current Price₹134.2525.4% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture01b2016201920222025202620282031Revenue ₹1.4bEarnings ₹370.2mAdvancedSet Fair ValueView all narrativesKronox Lab Sciences Limited 競合他社DIC IndiaSymbol: BSE:500089Market cap: ₹4.6bPlastiblends IndiaSymbol: BSE:523648Market cap: ₹4.3bHi-Green CarbonSymbol: NSEI:HIGREENMarket cap: ₹3.7bVipul OrganicsSymbol: BSE:530627Market cap: ₹3.7b価格と性能株価の高値、安値、推移の概要Kronox Lab Sciences過去の株価現在の株価₹134.2552週高値₹207.4952週安値₹96.00ベータ01ヶ月の変化2.68%3ヶ月変化11.99%1年変化-8.56%3年間の変化n/a5年間の変化n/aIPOからの変化-15.74%最新ニュースお知らせ • May 15Kronox Lab Sciences Limited to Report Q4, 2026 Results on May 20, 2026Kronox Lab Sciences Limited announced that they will report Q4, 2026 results at 12:08 PM, Indian Standard Time on May 20, 2026Buy Or Sell Opportunity • Apr 06Now 27% overvaluedOver the last 90 days, the stock has fallen 5.5% to ₹131. The fair value is estimated to be ₹103, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 18%.Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹119, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 17% over the past year.Buy Or Sell Opportunity • Feb 27Now 22% overvaluedOver the last 90 days, the stock has fallen 16% to ₹120. The fair value is estimated to be ₹98.59, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 18%.Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹1.79 (vs ₹1.77 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.79 (up from ₹1.77 in 3Q 2025). Revenue: ₹264.1m (up 10.0% from 3Q 2025). Net income: ₹65.9m (flat on 3Q 2025). Profit margin: 25% (down from 27% in 3Q 2025). The decrease in margin was driven by higher expenses.お知らせ • Feb 09Kronox Lab Sciences Limited to Report Q3, 2026 Results on Feb 14, 2026Kronox Lab Sciences Limited announced that they will report Q3, 2026 results at 12:08 PM, Indian Standard Time on Feb 14, 2026最新情報をもっと見るRecent updatesお知らせ • May 15Kronox Lab Sciences Limited to Report Q4, 2026 Results on May 20, 2026Kronox Lab Sciences Limited announced that they will report Q4, 2026 results at 12:08 PM, Indian Standard Time on May 20, 2026Buy Or Sell Opportunity • Apr 06Now 27% overvaluedOver the last 90 days, the stock has fallen 5.5% to ₹131. The fair value is estimated to be ₹103, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 18%.Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹119, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 17% over the past year.Buy Or Sell Opportunity • Feb 27Now 22% overvaluedOver the last 90 days, the stock has fallen 16% to ₹120. The fair value is estimated to be ₹98.59, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 18%.Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹1.79 (vs ₹1.77 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.79 (up from ₹1.77 in 3Q 2025). Revenue: ₹264.1m (up 10.0% from 3Q 2025). Net income: ₹65.9m (flat on 3Q 2025). Profit margin: 25% (down from 27% in 3Q 2025). The decrease in margin was driven by higher expenses.お知らせ • Feb 09Kronox Lab Sciences Limited to Report Q3, 2026 Results on Feb 14, 2026Kronox Lab Sciences Limited announced that they will report Q3, 2026 results at 12:08 PM, Indian Standard Time on Feb 14, 2026Reported Earnings • Nov 12Second quarter 2026 earnings released: EPS: ₹1.82 (vs ₹1.76 in 2Q 2025)Second quarter 2026 results: EPS: ₹1.82 (up from ₹1.76 in 2Q 2025). Revenue: ₹265.8m (up 6.9% from 2Q 2025). Net income: ₹66.8m (up 3.1% from 2Q 2025). Profit margin: 25% (in line with 2Q 2025).お知らせ • Nov 04Kronox Lab Sciences Limited to Report Q2, 2026 Results on Nov 11, 2025Kronox Lab Sciences Limited announced that they will report Q2, 2026 results on Nov 11, 2025Board Change • Sep 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Non Executive-Independent Women Director Krutika Negandhi was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Aug 06Kronox Lab Sciences Limited to Report Q1, 2026 Results on Aug 11, 2025Kronox Lab Sciences Limited announced that they will report Q1, 2026 results on Aug 11, 2025Upcoming Dividend • Aug 01Upcoming dividend of ₹0.50 per shareEligible shareholders must have bought the stock before 08 August 2025. Payment date: 17 September 2025. Payout ratio is a comfortable 7.3% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%).Reported Earnings • Jul 29Full year 2025 earnings released: EPS: ₹6.86 (vs ₹5.75 in FY 2024)Full year 2025 results: EPS: ₹6.86 (up from ₹5.75 in FY 2024). Revenue: ₹1.00b (up 12% from FY 2024). Net income: ₹254.7m (up 19% from FY 2024). Profit margin: 25% (up from 24% in FY 2024). The increase in margin was driven by higher revenue.お知らせ • Jul 28Kronox Lab Sciences Limited, Annual General Meeting, Aug 18, 2025Kronox Lab Sciences Limited, Annual General Meeting, Aug 18, 2025, at 11:00 Indian Standard Time.お知らせ • Jul 26Kronox Lab Sciences Limited announces Annual dividend, payable on September 17, 2025Kronox Lab Sciences Limited announced Annual dividend of INR 0.5000 per share payable on September 17, 2025, ex-date on August 08, 2025 and record date on August 08, 2025.Buy Or Sell Opportunity • Jul 07Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 45% to ₹202. The fair value is estimated to be ₹168, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.3% over the last 3 years. Earnings per share has grown by 22%.Valuation Update With 7 Day Price Move • Jun 26Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹187, the stock trades at a trailing P/E ratio of 27.3x. Average trailing P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 24% over the past year.Valuation Update With 7 Day Price Move • May 30Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹172, the stock trades at a trailing P/E ratio of 25.1x. Average trailing P/E is 27x in the Chemicals industry in India.分析記事 • May 28Not Many Are Piling Into Kronox Lab Sciences Limited (NSE:KRONOX) Just YetWhen close to half the companies in India have price-to-earnings ratios (or "P/E's") above 28x, you may consider Kronox...Reported Earnings • May 23Full year 2025 earnings released: EPS: ₹6.91 (vs ₹5.75 in FY 2024)Full year 2025 results: EPS: ₹6.91 (up from ₹5.75 in FY 2024). Revenue: ₹1.03b (up 14% from FY 2024). Net income: ₹254.7m (up 19% from FY 2024). Profit margin: 25% (up from 24% in FY 2024). The increase in margin was driven by higher revenue.お知らせ • May 19Kronox Lab Sciences Limited to Report Q4, 2025 Results on May 22, 2025Kronox Lab Sciences Limited announced that they will report Q4, 2025 results on May 22, 2025Reported Earnings • Feb 02Third quarter 2025 earnings released: EPS: ₹1.77 (vs ₹1.29 in 3Q 2024)Third quarter 2025 results: EPS: ₹1.77 (up from ₹1.29 in 3Q 2024). Revenue: ₹248.3m (up 20% from 3Q 2024). Net income: ₹65.3m (up 38% from 3Q 2024). Profit margin: 26% (up from 23% in 3Q 2024). The increase in margin was driven by higher revenue.お知らせ • Jan 23Kronox Lab Sciences Limited to Report Q3, 2025 Results on Jan 31, 2025Kronox Lab Sciences Limited announced that they will report Q3, 2025 results on Jan 31, 2025Valuation Update With 7 Day Price Move • Nov 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹191, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 32x in the Chemicals industry in India.New Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (₹6.87b market cap, or US$81.4m).お知らせ • Oct 31Kronox Lab Sciences Limited to Report Q2, 2025 Results on Nov 12, 2024Kronox Lab Sciences Limited announced that they will report Q2, 2025 results on Nov 12, 2024Valuation Update With 7 Day Price Move • Oct 14Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹175, the stock trades at a trailing P/E ratio of 30.8x. Average trailing P/E is 35x in the Chemicals industry in India.Valuation Update With 7 Day Price Move • Aug 29Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹182, the stock trades at a trailing P/E ratio of 31.9x. Average trailing P/E is 36x in the Chemicals industry in India.お知らせ • Aug 09Kronox Lab Sciences Limited, Annual General Meeting, Aug 30, 2024Kronox Lab Sciences Limited, Annual General Meeting, Aug 30, 2024, at 11:00 Indian Standard Time. Location: Block no. 353, Village: Ekalbara, Taluka: Padra, District: Vadodara 391440 IndiaReported Earnings • Aug 07First quarter 2025 earnings released: EPS: ₹1.67 (vs ₹0.64 in 1Q 2024)First quarter 2025 results: EPS: ₹1.67 (up from ₹0.64 in 1Q 2024). Revenue: ₹256.2m (up 19% from 1Q 2024). Net income: ₹61.5m (up 152% from 1Q 2024). Profit margin: 24% (up from 11% in 1Q 2024). The increase in margin was driven by higher revenue.お知らせ • Jul 29Kronox Lab Sciences Limited to Report Q1, 2025 Results on Aug 06, 2024Kronox Lab Sciences Limited announced that they will report Q1, 2025 results on Aug 06, 2024お知らせ • Jun 22Kronox Lab Sciences Limited to Report Q4, 2024 Results on Jun 28, 2024Kronox Lab Sciences Limited announced that they will report Q4, 2024 results on Jun 28, 2024Board Change • Jun 10Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Satish Kumar was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jun 08Kronox Lab Sciences Limited has completed an IPO in the amount of INR 1.30152 billion.Kronox Lab Sciences Limited has completed an IPO in the amount of INR 1.30152 billion. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 3,349,500 Price\Range: INR 136 Discount Per Security: INR 8.9216 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,914,000 Price\Range: INR 136 Discount Per Security: INR 8.9216 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,435,500 Price\Range: INR 136 Discount Per Security: INR 8.9216 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 2,871,000 Price\Range: INR 136 Discount Per Security: INR 8.9216 Transaction Features: Regulation S株主還元KRONOXIN ChemicalsIN 市場7D2.0%0.7%0.5%1Y-8.6%-2.6%-0.7%株主還元を見る業界別リターン: KRONOX過去 1 年間で-2.6 % の収益を上げたIndian Chemicals業界を下回りました。リターン対市場: KRONOXは、過去 1 年間で-0.7 % のリターンを上げたIndian市場を下回りました。価格変動Is KRONOX's price volatile compared to industry and market?KRONOX volatilityKRONOX Average Weekly Movement8.2%Chemicals Industry Average Movement7.2%Market Average Movement7.2%10% most volatile stocks in IN Market10.1%10% least volatile stocks in IN Market4.8%安定した株価: KRONOX 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: KRONOXの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2008n/aJogindersingh Jaswalwww.kronoxlabsciences.comクロノックス・ラボ・サイエンシズ社は、ファインケミカル、無機ケミカル、リン酸塩、金属ケミカルをインド国内外で製造・販売している。ACS試薬、LR、AR、GR試薬などのバルク試薬、オーラルケア、薬局方、食品・栄養補助食品、パーソナルケア・化粧品、動物用医薬品・動物用医薬品などのバルク原料、酒石酸塩、クエン酸塩、次亜リン酸塩、リン酸塩、水酸化物、EDTAおよび誘導体、超高純度化学品、カスタム仕様、特殊無水物などの特殊化学品を提供している。同社は2008年に設立され、インドのバドダラに拠点を置く。もっと見るKronox Lab Sciences Limited 基礎のまとめKronox Lab Sciences の収益と売上を時価総額と比較するとどうか。KRONOX 基礎統計学時価総額₹4.90b収益（TTM）₹259.73m売上高(TTM)₹1.01b19.2xPER（株価収益率4.9xP/SレシオKRONOX は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計KRONOX 損益計算書（TTM）収益₹1.01b売上原価₹496.42m売上総利益₹515.83mその他の費用₹256.10m収益₹259.73m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）7.00グロス・マージン50.96%純利益率25.66%有利子負債／自己資本比率2.6%KRONOX の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.4%現在の配当利回り7%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 13:49終値2026/05/21 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Kronox Lab Sciences Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 15Kronox Lab Sciences Limited to Report Q4, 2026 Results on May 20, 2026Kronox Lab Sciences Limited announced that they will report Q4, 2026 results at 12:08 PM, Indian Standard Time on May 20, 2026
Buy Or Sell Opportunity • Apr 06Now 27% overvaluedOver the last 90 days, the stock has fallen 5.5% to ₹131. The fair value is estimated to be ₹103, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 18%.
Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹119, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 17% over the past year.
Buy Or Sell Opportunity • Feb 27Now 22% overvaluedOver the last 90 days, the stock has fallen 16% to ₹120. The fair value is estimated to be ₹98.59, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 18%.
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹1.79 (vs ₹1.77 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.79 (up from ₹1.77 in 3Q 2025). Revenue: ₹264.1m (up 10.0% from 3Q 2025). Net income: ₹65.9m (flat on 3Q 2025). Profit margin: 25% (down from 27% in 3Q 2025). The decrease in margin was driven by higher expenses.
お知らせ • Feb 09Kronox Lab Sciences Limited to Report Q3, 2026 Results on Feb 14, 2026Kronox Lab Sciences Limited announced that they will report Q3, 2026 results at 12:08 PM, Indian Standard Time on Feb 14, 2026
お知らせ • May 15Kronox Lab Sciences Limited to Report Q4, 2026 Results on May 20, 2026Kronox Lab Sciences Limited announced that they will report Q4, 2026 results at 12:08 PM, Indian Standard Time on May 20, 2026
Buy Or Sell Opportunity • Apr 06Now 27% overvaluedOver the last 90 days, the stock has fallen 5.5% to ₹131. The fair value is estimated to be ₹103, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 18%.
Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹119, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 17% over the past year.
Buy Or Sell Opportunity • Feb 27Now 22% overvaluedOver the last 90 days, the stock has fallen 16% to ₹120. The fair value is estimated to be ₹98.59, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 18%.
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹1.79 (vs ₹1.77 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.79 (up from ₹1.77 in 3Q 2025). Revenue: ₹264.1m (up 10.0% from 3Q 2025). Net income: ₹65.9m (flat on 3Q 2025). Profit margin: 25% (down from 27% in 3Q 2025). The decrease in margin was driven by higher expenses.
お知らせ • Feb 09Kronox Lab Sciences Limited to Report Q3, 2026 Results on Feb 14, 2026Kronox Lab Sciences Limited announced that they will report Q3, 2026 results at 12:08 PM, Indian Standard Time on Feb 14, 2026
Reported Earnings • Nov 12Second quarter 2026 earnings released: EPS: ₹1.82 (vs ₹1.76 in 2Q 2025)Second quarter 2026 results: EPS: ₹1.82 (up from ₹1.76 in 2Q 2025). Revenue: ₹265.8m (up 6.9% from 2Q 2025). Net income: ₹66.8m (up 3.1% from 2Q 2025). Profit margin: 25% (in line with 2Q 2025).
お知らせ • Nov 04Kronox Lab Sciences Limited to Report Q2, 2026 Results on Nov 11, 2025Kronox Lab Sciences Limited announced that they will report Q2, 2026 results on Nov 11, 2025
Board Change • Sep 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Non Executive-Independent Women Director Krutika Negandhi was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 06Kronox Lab Sciences Limited to Report Q1, 2026 Results on Aug 11, 2025Kronox Lab Sciences Limited announced that they will report Q1, 2026 results on Aug 11, 2025
Upcoming Dividend • Aug 01Upcoming dividend of ₹0.50 per shareEligible shareholders must have bought the stock before 08 August 2025. Payment date: 17 September 2025. Payout ratio is a comfortable 7.3% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%).
Reported Earnings • Jul 29Full year 2025 earnings released: EPS: ₹6.86 (vs ₹5.75 in FY 2024)Full year 2025 results: EPS: ₹6.86 (up from ₹5.75 in FY 2024). Revenue: ₹1.00b (up 12% from FY 2024). Net income: ₹254.7m (up 19% from FY 2024). Profit margin: 25% (up from 24% in FY 2024). The increase in margin was driven by higher revenue.
お知らせ • Jul 28Kronox Lab Sciences Limited, Annual General Meeting, Aug 18, 2025Kronox Lab Sciences Limited, Annual General Meeting, Aug 18, 2025, at 11:00 Indian Standard Time.
お知らせ • Jul 26Kronox Lab Sciences Limited announces Annual dividend, payable on September 17, 2025Kronox Lab Sciences Limited announced Annual dividend of INR 0.5000 per share payable on September 17, 2025, ex-date on August 08, 2025 and record date on August 08, 2025.
Buy Or Sell Opportunity • Jul 07Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 45% to ₹202. The fair value is estimated to be ₹168, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.3% over the last 3 years. Earnings per share has grown by 22%.
Valuation Update With 7 Day Price Move • Jun 26Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹187, the stock trades at a trailing P/E ratio of 27.3x. Average trailing P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 24% over the past year.
Valuation Update With 7 Day Price Move • May 30Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹172, the stock trades at a trailing P/E ratio of 25.1x. Average trailing P/E is 27x in the Chemicals industry in India.
分析記事 • May 28Not Many Are Piling Into Kronox Lab Sciences Limited (NSE:KRONOX) Just YetWhen close to half the companies in India have price-to-earnings ratios (or "P/E's") above 28x, you may consider Kronox...
Reported Earnings • May 23Full year 2025 earnings released: EPS: ₹6.91 (vs ₹5.75 in FY 2024)Full year 2025 results: EPS: ₹6.91 (up from ₹5.75 in FY 2024). Revenue: ₹1.03b (up 14% from FY 2024). Net income: ₹254.7m (up 19% from FY 2024). Profit margin: 25% (up from 24% in FY 2024). The increase in margin was driven by higher revenue.
お知らせ • May 19Kronox Lab Sciences Limited to Report Q4, 2025 Results on May 22, 2025Kronox Lab Sciences Limited announced that they will report Q4, 2025 results on May 22, 2025
Reported Earnings • Feb 02Third quarter 2025 earnings released: EPS: ₹1.77 (vs ₹1.29 in 3Q 2024)Third quarter 2025 results: EPS: ₹1.77 (up from ₹1.29 in 3Q 2024). Revenue: ₹248.3m (up 20% from 3Q 2024). Net income: ₹65.3m (up 38% from 3Q 2024). Profit margin: 26% (up from 23% in 3Q 2024). The increase in margin was driven by higher revenue.
お知らせ • Jan 23Kronox Lab Sciences Limited to Report Q3, 2025 Results on Jan 31, 2025Kronox Lab Sciences Limited announced that they will report Q3, 2025 results on Jan 31, 2025
Valuation Update With 7 Day Price Move • Nov 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹191, the stock trades at a trailing P/E ratio of 30.5x. Average trailing P/E is 32x in the Chemicals industry in India.
New Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (₹6.87b market cap, or US$81.4m).
お知らせ • Oct 31Kronox Lab Sciences Limited to Report Q2, 2025 Results on Nov 12, 2024Kronox Lab Sciences Limited announced that they will report Q2, 2025 results on Nov 12, 2024
Valuation Update With 7 Day Price Move • Oct 14Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹175, the stock trades at a trailing P/E ratio of 30.8x. Average trailing P/E is 35x in the Chemicals industry in India.
Valuation Update With 7 Day Price Move • Aug 29Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹182, the stock trades at a trailing P/E ratio of 31.9x. Average trailing P/E is 36x in the Chemicals industry in India.
お知らせ • Aug 09Kronox Lab Sciences Limited, Annual General Meeting, Aug 30, 2024Kronox Lab Sciences Limited, Annual General Meeting, Aug 30, 2024, at 11:00 Indian Standard Time. Location: Block no. 353, Village: Ekalbara, Taluka: Padra, District: Vadodara 391440 India
Reported Earnings • Aug 07First quarter 2025 earnings released: EPS: ₹1.67 (vs ₹0.64 in 1Q 2024)First quarter 2025 results: EPS: ₹1.67 (up from ₹0.64 in 1Q 2024). Revenue: ₹256.2m (up 19% from 1Q 2024). Net income: ₹61.5m (up 152% from 1Q 2024). Profit margin: 24% (up from 11% in 1Q 2024). The increase in margin was driven by higher revenue.
お知らせ • Jul 29Kronox Lab Sciences Limited to Report Q1, 2025 Results on Aug 06, 2024Kronox Lab Sciences Limited announced that they will report Q1, 2025 results on Aug 06, 2024
お知らせ • Jun 22Kronox Lab Sciences Limited to Report Q4, 2024 Results on Jun 28, 2024Kronox Lab Sciences Limited announced that they will report Q4, 2024 results on Jun 28, 2024
Board Change • Jun 10Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Satish Kumar was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 08Kronox Lab Sciences Limited has completed an IPO in the amount of INR 1.30152 billion.Kronox Lab Sciences Limited has completed an IPO in the amount of INR 1.30152 billion. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 3,349,500 Price\Range: INR 136 Discount Per Security: INR 8.9216 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,914,000 Price\Range: INR 136 Discount Per Security: INR 8.9216 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,435,500 Price\Range: INR 136 Discount Per Security: INR 8.9216 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 2,871,000 Price\Range: INR 136 Discount Per Security: INR 8.9216 Transaction Features: Regulation S
